Citations

Clear

3030 citation(s) found for "Susan, M".

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Mato, Anthony R. , Sharman, Jeff P. , Kay, Neil E. , Kater, Arnon P. , Rogers, Kerry A. , Rhodes, Joanna , Skarbnik, Alan P , Eyre, Toby A. , Nabhan, Chadi , Lamanna, Nicole , Pagel, John M. , Ujjani, Chaitra S. , Brander, Danielle M. , Coombs, Catherine C. , Cheah, Chan Y. , Brown, Jennifer R. , Seymour, John F. , Woyach, Jennifer A. , Sharman, Jeff , Kay, Neil E , Rogers, Kerry A , Rhodes, Joanna , Eyre, Toby A , Sun, Clare , Cheah, Chan Yoon , Seymour, John F , Davids, Matthew S. , Roeker, Lindsey E. , Thompson, Meghan C , Goy, Andre Henri , Schuster, Stephen J. , Tam, Constantine S. , O’Brien, Susan , Shadman, Mazyar , Jain, Nitin

Mayo Clinic

Clinical Cancer Research | November 17, 2021 | Volume: 28 | Issue: 4 | Pages: 603-608

10.1158/1078-0432.ccr-21-1237 | PMID 34789482 Get It

Abstract The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.
Vaccination History and Risk of Lymphoma and Its Major Subtypes
Kleinstern, Geffen , Ansell, Stephen M. , Thompson, Carrie A. , Nowakowski, Grzegorz S. , Call, Timothy G. , Robinson, Dennis P. , Maurer, Matthew J. , Mwangi, Raphael , Feldman, Andrew L. , Novak, Anne J. , Ansell, Stephen M , Maurer, Matthew , Feldman, Andrew L , Kay, Neil E , Slager, Susan L , Cerhan, James R , Larson, Melissa C. , Kay, Neil E. , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 16, 2021 | Volume: 31 | Issue: 2 | Pages: 461-470

10.1158/1055-9965.epi-21-0383 | PMID 34782394 Get It

Abstract Background: Vaccinations have been hypothesized to play a role in lymphoma etiology, but there are few studies, mixed results, and limited data on lymphoma subtypes. Herein, we investigate the association of vaccinations with risk of major lymphoma subtypes. Methods: We studied 2,461 lymphoma cases and 2,253 controls enrolled from 2002 to 2014. Participants self-reported history of vaccinations against hepatitis A, hepatitis B, yellow fever, and influenza. Polytomous logistic regression was used to estimate OR and 95% confidence intervals (CI), adjusting for potential confounders. Results: After multivariable adjustment, vaccination against influenza was inversely associated with lymphoma (OR = 0.82; 95% CI, 0.66–1.02), which was stronger for last vaccination 1+ years before enrollment (OR = 0.71; 95% CI, 0.56–0.91) and for >5 influenza vaccinations (OR = 0.56; 95% CI, 0.46–0.68). Ever vaccination against hepatitis A (OR = 0.81; 95% CI, 0.66–1.00) but not hepatitis B (OR = 0.97; 95% CI, 0.81–1.18) was associated with lymphoma risk, although more recent vaccinations were inversely associated with lymphoma risk for both hepatitis A (<6 years before enrollment, OR = 0.56; 95% CI, 0.40–0.77) and hepatitis B (<9 years before enrollment, OR = 0.72; 95% CI, 0.55–0.93). Ever vaccination against yellow fever was inversely associated with risk (OR = 0.73; 95% CI, 0.55–0.96), and this did not vary by time since last vaccination. Although there was no overall statistical evidence for heterogeneity of vaccination history by lymphoma subtype, the only statistically significant inverse associations were observed for influenza and yellow fever vaccinations with diffuse large B-cell and follicular lymphoma. Conclusions: Selected vaccinations were inversely associated with lymphoma risk, with time since last vaccination relevant for some of these vaccines. Impact: Vaccinations against hepatitis A, hepatitis B, yellow fever, and influenza are unlikely to increase lymphoma risk.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Chang, Julie , Christian, Beth , Advani, Ranjana H. , Bartlett, Nancy L. , Vos, Sven de , Dholaria, Bhagirathbhai , Fakhri, Bita , Fayad, Luis , Glenn, Martha, Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Krivacic, Susan, LaCasce, Ann S. , Narkhede, Mayur , Rabinovitch, Rachel , Roberts, Kenneth B. , Smith, Stephen D. , Svoboda, Jakub , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Dholaria, Bhagirathbhai R , Bartlett, Nancy L , Advani, Ranjana H , Fakhri, Bita , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Budde, Lihua E. , Caimi, Paolo F. , Habermann, Thomas M. , Hsi, Eric D. , Hu, Boyu , Kelsey, Chris R. , Khan, Nadia , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 15, 2021 | Volume: 19 | Issue: 11 | Pages: 1218-1230

10.6004/jnccn.2021.0054 | PMID 34781267 Get It

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Jacobsen, Eric D. , Baiocchi, Robert A. , Buhtoiarov, Ilia N. , Butler, Erin , Goodman, Aaron M. , Gratzinger, Dita , Higman, Meghan A., Hogarty, Michael D. , Jankú, Filip , Raldow, Anne C., Stefanovic, Alexandra, Tantravahi, Srinivas K. , Walkovich, Kelly, Bergman, Mary Anne, Darlow, Susan, Go, Ronald S. , Butler, Erin B. , Campbell, Patrick , Coulter, Donald W. , Diamond, Eli L. , Flagg, Aron , Goyal, Gaurav , Hendrie, Paul C. , Karmali, Reem , Morgan, David , Raldow, Ann C. , Zhang, Ling

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 15, 2021 | Volume: 19 | Issue: 11 | Pages: 1277-1303

10.6004/jnccn.2021.0053 | PMID 34781268 Get It

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (“watch and wait”) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.
Engineering Prone Patient Positioning for Spine Surgery to Reduce Risk of Clinician Injury
Lowndes, Bethany R. , Kraft, Sarah , Asiedu, Gladys B. , Woolley, Sandra M., Loynes, Lynn, Huddleston, Paul H., Huddleston, P.M. , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | November 12, 2021 | Volume: 65 | Issue: 1 | Pages: 515-519

10.1177/1071181321651274 Get It

Operating room throughput variability with spinal procedures revealed task inefficiency and potential safety concerns. Using the DMAIC framework (Define, Measure, Analyze, Improve, Control), a transdisciplinary team conducted a quality improvement (QI) research project to identify and address safety concerns with prone patient positioning. The main problem with patient positioning was undefined standard practice. Clinicians reported prone patient positioning for spinal surgery patients is physically demanding. Thus, the team conducted a rapid upper limb assessment for injury risk during patient positioning and identified a greater risk of clinician injury in the manual transfer process. The QI research team recommended the mechanical process of rotating patients with the Jackson Table to improve workload for the Surgical Team and developed training and design enhancements to support this workflow. The DMAIC quality framework enabled clinician collaboration with researchers to develop interventions to support a standardized process during prone patient positioning with the Jackson Table.
Introducing Exoskeletons into the Operating Room: A pilot study with vascular surgeons
Wang, Tianke , Mendes, Bernardo C. , Tetteh, Emmanuel , Smith, Tianqi Gao, Tetteh, Emmanuel , Hallbeck, M. Susan , Norasi, Hamid

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | November 12, 2021 | Volume: 65 | Issue: 1 | Pages: 1376-1380

10.1177/1071181321651212 Get It

The main goal of this pilot study was to create, implement and evaluate a strategy for introducing exoskeletons in the operating room (OR) at a quaternary care academic hospital. The strategy consisted of operating-room-specific considerations, introducing exoskeletons to surgeons, and a post-surgery survey. Three male attending vascular surgeons participated in eleven data collections to date. Low interference with surgeon’s ability to perform surgery was found for all surgical procedures, except for two open abdominal aortic procedures. The surgeons reported little to no limit on range of motion, except for one open abdominal aortic procedure. Lower than expected perceived improvement of ability to perform surgery and increase of physical comfort was self-reported. The responses indicate that the surgeons are willing to keep trying an exoskeleton intervention. In conclusion, a feasible process was created to introduce passive exoskeleton as an ergonomic intervention to vascular surgeons in their ORs.
Correlation between workload and teamwork among residents in DIEP Flap surgery
Wang, Tianke , Harless, Christin A., Nguyen, Minh-Doan T. , Norasi, Hamid , Law, Katherine E. , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | November 12, 2021 | Volume: 65 | Issue: 1 | Pages: 1210-1214

10.1177/1071181321651083 Get It

The goal of this study was to evaluate residents’ workload and teamwork and the correlation between their workload and teamwork subscales during deep inferior epigastric perforator (DIEP) flap surgery. Ten residents who assisted during DIEP flap procedures completed an electronic survey following each DIEP flap procedure from July 2019 to August 2020. The survey contained items from the NASA-TLX and SURG-TLX and questions to measure teamwork subscales. Across 29 surgical cases, 38 surveys were recorded. Overall, the means of workload subscales were mostly greater than 10 and less than 15 (range=020) and the means of all teamwork subscales were greater than 15 (range=0-20). Good teamwork was correlated with lower distractions (Rs= -0.36 to -0.48) and better performance (Rs=0.35 to 0.52). Also, all the teamwork subscales were highly correlated (Rs= 0.59 to 0.92). Our findings suggest that good teamwork, low distractions, and successful performance are generally observed together; however, a causative relationship could not be established based on these results.
Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words?
Meagher, Karen M. , Finn, Kelsey Stuttgen , Curtis, Susan , Borucki, Jack, Beck, Annika T., Cheema, Amal , Sharp, Richard R. , Stuttgen Finn, Kelsey, Curtis, Susan H , Cheema, Amal W, Sharp, Richard R , Meagher, Karen M , Stuttgen, Kelsey

Mayo Clinic

Clinical and Translational Science | November 10, 2021 | Volume: 15 | Issue: 3 | Pages: 721-731

10.1111/cts.13193 | PMID 34755460 Get It

AbstractAs pharmacogenomic (PGx) testing increases in popularity, lay concepts of drug‐gene interactions set the stage for shared decision making in precision medicine. Few studies explore what recipients of PGx results think is happening in their bodies when a drug‐gene interaction is discovered. To characterize biobank participants’ understanding of PGx research results, we conducted a focus group study, which took place after PGx variants conferring increased risk of dihydropyrimidine dehydrogenase (DPD) deficiency were disclosed to biobank contributors. DPD deficiency confers an increased risk of adverse reaction to commonly used cancer chemotherapeutics. Ten focus groups were conducted, ranging from two to eight participants. Fifty‐four individuals participated in focus groups. A framework approach was used for descriptive and explanatory analysis. Descriptive themes included participants’ efforts to make sense of PGx findings as they related to: (1) health implications, (2) drugs, and (3) genetics. Explanatory analysis supplied a functional framework of how participant word choices can perform different purposes in PGx communication. Results bear three main implications for PGx research‐related disclosure. First, participants’ use of various terms suggest participants generally understanding their PGx results, including how positive PGx results differ from positive disease susceptibility genetic results. Second, PGx disclosure in biobanking can involve participant conflation of drug‐gene interactions with allergies or other types of medical reactions. Third, the functional framework suggests a need to move beyond a deficit model of genetic literacy in PGx communication. Together, findings provide an initial evidence base for supporting bidirectional expert‐recipient PGx results communication.
ADHD Diagnosis and Treatment Guidelines: A Historical Perspective
Wolraich, Mark L., Chan, Eugenia, Froehlich, Tanya E. , Lynch, Rachel L., Bax, Ami , Redwine, Susan T., Ihyembe, Demvihin, Hagan, Joseph F.

Mayo Clinic

Pediatric Collections: ADHD: Evaluation and Care | November 8, 2021 | Volume: No volume available | Issue: No issue available | Pages: 75-83

10.1542/9781610024129-part01-adhd Get It

Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with Fusobacterium nucleatum and Its Subspecies animalis
Borozan, Ivan , Zaidi, Syed Hassan Ejaz , Harrison, Tabitha A. , Phipps, Amanda I. , Zheng, Jiayin , Lee, Stephen Dongsoo , Trinh, Quang M. , Steinfelder, Robert S. , Adams, Jeremy , Banbury, Barbara L. , Berndt, Sonja I. , Bullman, Susan , Cao, Yin , Figueiredo, Jane C. , Giannakis, Marios , Luo, Xuemei , Nishihara, Reiko , Papadopoulos, Nickolas , Reid, Emma , Thibodeau, Stephen N. , Harlid, Sophia , Gsur, Andrea , Gallinger, Steven, Ferretti, Vincent , Peters, Ulrike , Lee, Stephen , Brezina, Stefanie , Buchanan, Daniel D , Farris, Alton B , Figueiredo, Jane C , Mardis, Elaine R. , Harlid, Sophia , Um, Caroline Y , Hsu, Li , Gsur, Andrea , Campbell, Peter T , Ogino, Shuji , Sun, Wei , Hudson, Thomas J , Peters, Ulrike , Zheng, Yingye , Cao, Yin , Harrison, Tabitha A , Trinh, Quang M , Brezina, Stefanie , Buchanan, Daniel D. , Farris, Alton B. , Heisler, Lawrence E. , Hopper, John L. , Lin, Yi , Qu, Conghui , Reid, Emma E.G., Um, Caroline Y. , Campbell, Peter T. , Newcomb, Polly A. , Sun, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 4, 2021 | Volume: 31 | Issue: 1 | Pages: 210-220

10.1158/1055-9965.epi-21-0463 | PMID 34737207 Get It

Abstract Background: Fusobacterium nucleatum (F. nucleatum) activates oncogenic signaling pathways and induces inflammation to promote colorectal carcinogenesis. Methods: We characterized F. nucleatum and its subspecies in colorectal tumors and examined associations with tumor characteristics and colorectal cancer–specific survival. We conducted deep sequencing of nusA, nusG, and bacterial 16s rRNA genes in tumors from 1,994 patients with colorectal cancer and assessed associations between F. nucleatum presence and clinical characteristics, colorectal cancer–specific mortality, and somatic mutations. Results: F. nucleatum, which was present in 10.3% of tumors, was detected in a higher proportion of right-sided and advanced-stage tumors, particularly subspecies animalis. Presence of F. nucleatum was associated with higher colorectal cancer–specific mortality (HR, 1.97; P = 0.0004). This association was restricted to nonhypermutated, microsatellite-stable tumors (HR, 2.13; P = 0.0002) and those who received chemotherapy [HR, 1.92; confidence interval (CI), 1.07–3.45; P = 0.029). Only F. nucleatum subspecies animalis, the main subspecies detected (65.8%), was associated with colorectal cancer–specific mortality (HR, 2.16; P = 0.0016), subspecies vincentii and nucleatum were not (HR, 1.07; P = 0.86). Additional adjustment for tumor stage suggests that the effect of F. nucleatum on mortality is partly driven by a stage shift. Presence of F. nucleatum was associated with microsatellite instable tumors, tumors with POLE exonuclease domain mutations, and ERBB3 mutations, and suggestively associated with TP53 mutations. Conclusions: F. nucleatum, and particularly subspecies animalis, was associated with a higher colorectal cancer–specific mortality and specific somatic mutated genes. Impact: Our findings identify the F. nucleatum subspecies animalis as negatively impacting colorectal cancer mortality, which may occur through a stage shift and its effect on chemoresistance.